(NASDAQ: JSPR) Jasper Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Jasper Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast JSPR's revenue for 2026 to be $162,533,320, with the lowest JSPR revenue forecast at $162,533,320, and the highest JSPR revenue forecast at $162,533,320. On average, 1 Wall Street analysts forecast JSPR's revenue for 2027 to be $372,851,436, with the lowest JSPR revenue forecast at $372,851,436, and the highest JSPR revenue forecast at $372,851,436.
In 2028, JSPR is forecast to generate $1,115,953,775 in revenue, with the lowest revenue forecast at $1,115,953,775 and the highest revenue forecast at $1,115,953,775.